Financials in USD. Standardized financial statements.
A compact view of how LakeShore Biopharma Co., Ltd turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue? | $614.96M | $573.42M | $687.20M | $502.95M | $257.02M |
| Revenue Growth? | +7.2% | -16.6% | +36.6% | +95.7% | 0.0% |
| Cost of Revenue? | $107.77M | $117.69M | $153.36M | $121.46M | $59.66M |
| Gross Profit? | $507.19M | $455.73M | $533.84M | $381.49M | $197.36M |
| Gross Margin? | +82.5% | +79.5% | +77.7% | +75.9% | +76.8% |
| Operating Expenses? | $593.48M | $901.56M | $673.22M | $500.45M | $323.21M |
| Operating Income? | -$86.29M | -$445.83M | -$139.38M | -$118.96M | -$125.85M |
| EBITDA? | -$48.54M | -$368.66M | -$76.80M | -$67.20M | -$116.78M |
| Income Before Tax | -$100.93M | -$455.19M | -$282.34M | -$231.73M | -$190.98M |
| Income Tax Expense | -$946,873 | -$21.73M | $1.13M | $4.94M | $17.45M |
| Net Income? | -$99.98M | -$433.46M | -$145.48M | -$236.67M | -$191.83M |
| EPS? | $-0.94 | $-4.05 | $-1.88 | $-0.02 | $-6.67 |
| Diluted EPS? | $-0.94 | $-4.05 | $-1.88 | $-0.02 | $-6.67 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality